順灝股份(002565.SZ)順灝投資及王丹累計減持2151萬股減持計劃已實施完畢
格隆匯8月20日丨順灝股份(002565.SZ)公佈,近日公司收到順灝投資及王丹《股份減持比例達到1%暨股份減持計劃實施完成的告知函》,獲悉順灝投資和王丹通過集中競價交易和大宗交易的方式累計減持公司無限售流通股2151萬股,佔公司總股本的2.0289%。且減持計劃實施期間順灝投資及王丹通過集中競價減持股數佔公司總股本比例不超過1.973%,符合預披露的股份減持計劃數量要求,此次減持計劃已實施完畢。
此次減持後,順灝投資持股比例由23.25%降至22.27%;王丹持股比例由13.41%降至12.43%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.